1[1]RiziR DG, Healy S, Margulis A, et al. A new clinical classification for hospital prognosis of unstable angina pectoris. Am J Cardiol, 1995;75(15) :993～997
2[2]Waters D, Lam J, Theroux P, et al. Newer concepts in the treatment of unstable angina pectoris. Am J Cardiol, 1992;68(12) :34c～41c
3[3]Fareed P, Walengal, Kaman A. A modified stasis thromtosis model to study the antithromtobic actions of heparin and fractions. Semin Thrombi Hemost, 1995; 11:155
5[5]Fareed J, Hoppensteadt DA. Pharmacology of the low-molecular-weight heparins. Semin Thromb Hemost, 1996; 22(suppl 2): 13～18
6Wang Q L，Jpn J Pharmacol，2000年，82卷，4期，326页
7Yu X Y，Am J Respir Cell Mol Biol，1994年，11卷，2期，188页
8Kay R,Wong KS,Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med, 1995,333: 1588-1593.
9Hommel M. For the FISSbis investigators group: Fraxiparine in ischemic stroke study (FISSbis). Cerebrovasc Dis, 1998, 8(suppl4):19.
10The International Stroke Trial(IST) :A randomised trial of aspirin, subcutaneous heparin,both, or neither among 19 435 patients with acute ischemic stroke. International Stroke Trial Collaborative Group. Lancet,1997 ,349:1569-1581.
